In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Why it feels like everyone is getting sick right now
South Africa takes Israel to UN court
Why Taiwan’s election tests China’s authority
Hard truths about ‘gentle parenting’
What’s in store for Canada’s economy in 2024
New attacks threaten to push Israel-Hamas war beyond borders
Has the promise of plant-based meats gone bust?
Where grief fits into Canada’s healthcare system
It was a rough year for Trudeau – what will 2024 bring?
The story of the world's most premature twins to survive
Ford and the never-ending Ontario Place saga
The hunt for dark matter, two kilometres under Sudbury
Butter, sugar and a pinch of family
A wallet was sent to The Globe with a letter from a dying man
The lost art of human pinsetting
The myth and the reality of Newfoundland’s giant squids
The complicated art of political cartoons, with Brian Gable
The man accused of selling toxic substances used for suicide
What a bad back tells us about Canada’s chronic pain problem
School shutdowns, hospital delays and a massive strike in Quebec
Create your
podcast in
minutes
It is Free
Front Burner
At Issue
The Daily
Today, Explained
Morning Wire